港股创新药早盘表现亮眼，港股创新药ETF（159567）涨超2%，医药行业进入“创新驱动”的营收时代

Core Viewpoint - The Hong Kong stock market showed strong performance in the early session, particularly in the innovative drug sector, indicating a robust demand for pharmaceuticals and a shift towards an "innovation-driven" revenue era in the industry [1] Group 1: Market Performance - Innovative drug stocks performed well, with notable gains: Zai Lab rose over 6%, CanSino Biologics-B increased over 5%, and Rongchang Biologics climbed over 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose over 2%, reflecting the positive sentiment in the sector [1] Group 2: Industry Insights - Analysts attribute the pharmaceutical industry's ability to reach new highs despite ongoing challenges to the continuous demand for medical solutions and the increasing number of unmet needs [1] - Pharmaceutical companies are significantly increasing their R&D investments to address these unmet needs, positioning China as a key player in global innovative drug development [1] - The trend of overseas licensing has been rising year after year, further emphasizing the industry's shift towards innovation [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]